With 0.64 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.83 whereas the lowest price it dropped to was $1.76. The 52-week range on PLX shows that it touched its highest point at $1.90 and its lowest point at $0.82 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.74.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PLX was up-trending over the past week, with a rise of 11.59%, but this was up by 57.76% over a month. Three-month performance surged to 75.96% while six-month performance rose 55.08%. The stock gained 12.27% in the past year, while it has gained 2.81% so far this year. A look at the trailing 12-month EPS for PLX yields -0.14 with Next year EPS estimates of 0.63. For the next quarter, that number is 0.08. This implies an EPS growth rate of -77.78% for this year and 3050.00% for next year.
Float and Shares Shorts:
At present, 73.63 million PLX shares are outstanding with a float of 68.06 million shares on hand for trading. On 2024-10-31, short shares totaled 3.1 million, which was 421.0 higher than short shares on 1727654400. In addition to Mr. Dror Bashan as the firm’s President, CEO & Director, Mr. Eyal Rubin M.B.A. serves as its Senior VP, CFO, Treasurer & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.05198 of PLX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, PLX reported revenue of $17959000.0 and operating income of $3991000.0. The EBITDA in the recently reported quarter was $4471000.0 and diluted EPS was $0.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With PLX analysts setting a high price target of 14.0 and a low target of 14.0, the average target price over the next 12 months is 14.0. Based on these targets, PLX could surge 665.03% to reach the target high and rise by 665.03% to reach the target low. Reaching the average price target will result in a growth of 665.03% from current levels.
Analysts have provided yearly estimates in a range of $0.02 being high and $0.02 being low. For PLX, this leads to a yearly average estimate of $0.02. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
